SCHEMBL20802114

SCHEMBL20802114

CC1OC(O[C@H](COc2c(-c3ccc(O)c(O)c3)oc3cc(O)cc(O)c3c2=O)C(O)C(O)C(O)CO)C(O)C(O)C1O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ P4HB P07237 7/20 0.66
▸ KDM4E B2RXH2 7/20 0.66
▸ EPHX2 P34913 5/20 0.66
▸ MAOA P21397 4/20 0.66
▸ XDH P47989 4/20 0.66
▸ AKR1B1 P15121 4/20 0.66
▸ L3MBTL1 Q9Y468 3/20 0.66
▸ SLCO2B1 O94956 3/20 0.66
▸ PIM2 Q9P1W9 2/20 0.66
▸ CA12 O43570 2/20 0.66
▸ CA2 P00918 2/20 0.66
▸ CA4 P22748 2/20 0.66
▸ CA7 P43166 2/20 0.66
▸ ALDH1A1 P00352 1/20 0.66
▸ MAPT P10636 4/20 0.60
▸ GAA P10253 4/20 0.60
▸ POLB P06746 3/20 0.60
▸ KDM1A O60341 2/20 0.60
▸ HMGB1 P09429 2/20 0.60
▸ ADRA2C P18825 2/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20802116 0.93 P4HB (0.62) P4HBKDM4EEPHX2MAOAXDH
SCHEMBL20802113 0.91 GAA (0.69) P4HBKDM4EEPHX2MAOAXDH
SCHEMBL20802174 0.90 KDM4E (0.64) P4HBKDM4EEPHX2MAOAXDH
SCHEMBL20802175 0.85 EPHX2 (0.71) P4HBKDM4EEPHX2MAOAXDH
SCHEMBL19490598 0.83 POLH (0.70) P4HBKDM4EEPHX2MAOAXDH
SCHEMBL14414400 0.81 KDM4E (0.61) P4HBKDM4EEPHX2MAOAXDH
SCHEMBL17209333 0.81 P4HB (0.66) P4HBKDM4EEPHX2MAOAXDH
Quercitrin SCHEMBL1697151 0.80 P4HB (1.00) P4HBKDM4EEPHX2MAOAXDH
Quercitrin SCHEMBL5456136 0.80 P4HB (1.00) P4HBKDM4EEPHX2MAOAXDH
Quercitrin SCHEMBL117644 0.80 P4HB (1.00) P4HBKDM4EEPHX2MAOAXDH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10765128-B2 Composition for prevention or treatment of metabolic syndrome or for antioxidation containing black bean leaf extracts and flavonol glysosides isolated therefrom as active ingredients KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2020-09-08 — — US disclosed
US-20190075823-A1 COMPOSITION FOR PREVENTION OR TREATMENT OF METABOLIC SYNDROME OR FOR ANTIOXIDATION CONTAINING BLACK BEAN LEAF EXTRACTS AND FLAVONOL GLYSOSIDES ISOLATED THEREFROM AS ACTIVE INGREDIENTS KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2019-03-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10765128-B2 Composition for prevention or treatment of metabolic syndrome or for antioxidation containing black bean leaf extracts and flavonol glysosides isolated therefrom as active ingredients GPX1, GSTP1, GSS P4HB 1549/4885KDM4E 4058/4885EPHX2 3943/4885
US-20190075823-A1 COMPOSITION FOR PREVENTION OR TREATMENT OF METABOLIC SYNDROME OR FOR ANTIOXIDATION CONTAINING BLACK BEAN LEAF EXTRACTS AND FLAVONOL GLYSOSIDES ISOLATED THEREFROM AS ACTIVE INGREDIENTS GPX1, GSTP1, PON1 P4HB 1470/4885KDM4E 4169/4885EPHX2 2927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback